Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Sino Biopharmaceutical Limited (“Sino Biopharm” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in ...

Akeso's first overall survival readout for its Keytruda challenger caused a violent market reaction. AstraZeneca disclosed ...

ET Net News Agency, 14 April 2025] Daiwa raised the target price for Sino Biopharm (01177) to HKD4 from HKD3.5 and maintained the "buy" rating. The research house said it raises ...

Sino Biopharm, for example, which was founded in 2000 and is headquartered in Hong Kong and Beijing, has partnered with HSBC as it rolls out new therapies centring mainly on oncology, hepatology ...

ET Net News Agency, 28 April 2025] SINO BIOPHARM (01177) fell 3.3% to HK$3.82. It hits an intra-day low of HK$3.82, and an intra-day high of HK$3.94. The total shares traded was 5.98 million, with a ...

Your one-stop source for comprehensive reagent solutions and CRO services Sino Biological, an international reagent supplier and service provider, specializes in recombinant protein production and ...